Clinical trial · Observational
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
Comparison of Changes in Tumor Burden (Toral Tumor Volume [TMTV] and Total Lesion Activity [TLA]) in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in the Monitoring of Metastatic Castration-resistant Prostate Cancer Treated With 177Lutetium-PSMA-617
NCT06461689CI-TRIAL-00115842PROLUTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To demonstrate the prognostic value of using post-therapy 177Lu-PSMA SPECT/CT versus 68Ga-PSMA-11 PET/CT in mCPRC patients progressing despite chemotherapy and treated with 177Lu-PSMA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 177Lu-PSMA-617 | Drug | Lutetium (177lu) Vipivotide Tetraxetan | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- patient treated as part of mCPRC
- description
- All patients treated with 177Lu-PSMA had post-therapy 68Ga-PSMA PET and 177Lu-PSMA-617 SPECT/CT.
- interventionNames
- Drug: 177Lu-PSMA-617
Primary outcomes (2)
- measure
- Measurement of TMTV (total metabolic tumor volume)
- timeFrame
- 12 months
- description
- Measurement of TMTV (total metabolic tumor volume) on 68Ga-PSMA-11 PET/CT (pre-treatment, after 4th treatment and after 6th treatment) and on SPECT/CT (after each treatment).
- measure
- Measurement of TLA (total lesion activity)
- timeFrame
- 12 months
- description
- Measurement of TLA (total lesion activity) on 68Ga-PSMA-11 PET/CT (pre-treatment, after 4th treatment and after 6th treatment) and on SPECT/CT (after each treatment).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patient who received a dose of 177lu-PSMA * patient who had imaging by 68Ga-PSMA * patient treated in Nancy hospital for its cancer prostate Exclusion Criteria: * no social security * no acceptation to participating in retrospective study
References
Publications (1)
- RESULTKunsch J, Zaragori T, Olivier P, Claudin M, Marie PY, Raymond P, Heyer S, Verger A, Imbert L, Boursier C. Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [177Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360 degrees Cadmium-Zinc-Telluride SPECT. J Nucl Med. 2025 Nov 3;66(11):1695-1702. doi: 10.2967/jnumed.125.270358. PMID 40935614